KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Jul 04, 2025 >>  ABB India 5862.65  [ -0.13% ]  ACC 1964.05  [ 0.39% ]  Ambuja Cements 594.7  [ 1.05% ]  Asian Paints Ltd. 2424.8  [ -0.23% ]  Axis Bank Ltd. 1177.55  [ 0.62% ]  Bajaj Auto 8431.35  [ 0.56% ]  Bank of Baroda 240.75  [ -0.66% ]  Bharti Airtel 2017.45  [ 0.00% ]  Bharat Heavy Ele 260.15  [ 1.03% ]  Bharat Petroleum 346.3  [ 4.54% ]  Britannia Ind. 5768.9  [ -0.45% ]  Cipla 1513.5  [ 0.33% ]  Coal India 386.05  [ -0.10% ]  Colgate Palm. 2447  [ 0.10% ]  Dabur India 495.25  [ 0.77% ]  DLF Ltd. 835.95  [ 0.77% ]  Dr. Reddy's Labs 1305.1  [ 0.92% ]  GAIL (India) 193.35  [ 0.36% ]  Grasim Inds. 2806.4  [ -0.34% ]  HCL Technologies 1725.35  [ 0.86% ]  HDFC Bank 1989.25  [ 0.18% ]  Hero MotoCorp 4346  [ 0.74% ]  Hindustan Unilever L 2339.8  [ 1.19% ]  Hindalco Indus. 699.35  [ 0.87% ]  ICICI Bank 1442.65  [ 1.15% ]  Indian Hotels Co 747.05  [ -0.16% ]  IndusInd Bank 856.2  [ -0.72% ]  Infosys L 1640.2  [ 1.36% ]  ITC Ltd. 412.55  [ -0.24% ]  Jindal St & Pwr 952.85  [ -0.33% ]  Kotak Mahindra Bank 2128.4  [ 0.10% ]  L&T 3593.7  [ 0.31% ]  Lupin Ltd. 1976.85  [ 1.09% ]  Mahi. & Mahi 3161.75  [ -0.41% ]  Maruti Suzuki India 12648.75  [ -0.81% ]  MTNL 50.25  [ -1.47% ]  Nestle India 2392.05  [ 0.15% ]  NIIT Ltd. 129.2  [ -0.58% ]  NMDC Ltd. 68.8  [ -0.42% ]  NTPC 335.5  [ 0.21% ]  ONGC 245.3  [ 0.53% ]  Punj. NationlBak 110.85  [ 0.59% ]  Power Grid Corpo 294.1  [ 0.14% ]  Reliance Inds. 1527.4  [ 0.56% ]  SBI 811.85  [ 0.59% ]  Vedanta 458.85  [ 0.11% ]  Shipping Corpn. 221.35  [ -0.23% ]  Sun Pharma. 1676.65  [ -0.13% ]  Tata Chemicals 939  [ -0.58% ]  Tata Consumer Produc 1089.6  [ 0.07% ]  Tata Motors 688.95  [ -0.21% ]  Tata Steel 163  [ -1.72% ]  Tata Power Co. 400.95  [ 0.30% ]  Tata Consultancy 3420.95  [ 0.59% ]  Tech Mahindra 1655.05  [ -1.07% ]  UltraTech Cement 12505.6  [ 0.90% ]  United Spirits 1378.4  [ -0.27% ]  Wipro 270.05  [ 1.10% ]  Zee Entertainment En 147.2  [ 2.36% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....

Forex

  • Loading....

VENUS REMEDIES LTD.

04 July 2025 | 12:00

Industry >> Pharmaceuticals

Select Another Company

ISIN No INE411B01019 BSE Code / NSE Code 526953 / VENUSREM Book Value (Rs.) 369.73 Face Value 10.00
Bookclosure 23/09/2024 52Week High 477 EPS 33.90 P/E 13.13
Market Cap. 595.23 Cr. 52Week Low 270 P/BV / Div Yield (%) 1.20 / 0.00 Market Lot 1.00
Security Type Other

History of Company

The company history sections lists out major chronological events that happened to the company.
M/s VENUS REMEDIES LTD. was incorporated as a private limited company on 15th day of Sept. 1989 in the name and style of Venus Glucose Pvt Ltd, and subsequently converted into a public limited company, vide fresh certificate of incorporation dated 19th Sept. 1994 and the name was converted as "Venus Remedies Ltd" under the Companies Act, issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh at Jalandhar. The company started its production in the year 1991 with Intravenous/Intramuscular (IV/IM) injectable forms at its running unit located at 52, Ind. Area. Phase-I, Panchkula Distt. Ambala (Haryana). Subsequently the company introduced Eye/Ear/Nasal Drops during the year 1994. During the same year, the company also expanded its existing capacity from 9 lacs pieces per annum to 15 lacs pieces per annum and that of 9 lacs pieces to 20 lacs pieces per annum of IV fluids section and vial section respectively. And, during 1994, the company has also certified as "WHO-GMP" (Good practices in manufacturing and quality control) as specified by WHO, Geneva by the State Drug Controller of Haryana. MAIN OBJECTS OF THE COMPANY The main objects of the company as set out in its Memorandum of Association are : 1. To manufacture, import, export of intravenous transfusion fluids and formations such as dextrose, dextrose with sodium chloride, normal saline, isolate P, isolate M, isolate G, isolate E, Mannitol etc. in various concentrations, intravenous solution for dialysis purposes, ACD Sterile bottles for blood collections, pharmaceutical parenteral preparations like Aminophylline, Adernaline, Water for injection, Chloroquine Sulphate, Sodium bi-carbonate, Analgin, Diazepam, Oxyphenbutazone & other injectables. 2. To carry on the business of deriving, formulating, purchasing, producing manufacturing, preparing, processing, mising, compounding, refining, marketing, distributing, selling and trading in pharmaceuticals, Chemicals, cosmetics, perfumes, medicines and drugs of all kinds, specifications and descriptions, and to do so especially in respect of all kinds of analgesics and antipyretics. 3. To carry on the business of purchasing, producing manufacturing, preparing, processing, mixing, compounding, refining, marketing, distributing, selling and trading in all classes and kinds of raw material ingredients, mixtures, compounds and derivatives connected to, intermediate in or associated with the manufacture production and sale of pharmaceuticals, chemicals medicines and drugs. 4. To carry on the business of vialling, bottling, packing. repacking and processing of capsules, syrups, tablets, injectables, aerosoles and ointment, bulk drugs and chemicals. 2005 -Venus Remedies successfully launches its Brand "Ronem" -Venus Remedies announces Strategic Marketing tie up with M/S Cadila Pharmaceuticals Ltd - M/s Themis Medicare Ltd enters into a Strategic Marketing Tie Up with Venus Remedies Ltd. -Delist equity shares from Delhi, Jaipur & Ahmedabad Stock Exchanges. -Venus Remedies has entered into Strategic Marketing Agreement with Merck Specialties Pvt Ltd, a wholly owned Subsidiary of Merck Ltd, Darmstadt, Germany, for its Oncology range of products. -Venus Remedies sets up a wholly owned subsidiary in Germany 2006 -Venus Remedies Ltd has informed that a Company has been granted three prestigious ISO certifications -Venus Remedies in-licenses product Technology from USA 2007 -Venus Remedies Ltd has signed an agreement with M/s. Pharma Match R&D B.V. a limited Company based at Amsterdam, Netherlands for jointly preparing, registering and marketing an EU E-CTD Dossier for a latest generation Carbapenem Injectible. 2008 -Venus facilities Accredited with European GMP Certification. -Venus Remedies Ltd has informed that the Company's manufacturing facilities have been approved by the G.F.T.O of Syria for manufacturing and exporting its products to Syria. -Venus Remedies - European AMP Accreditation for Venus Oncology Facilities. -Venus Remedies Ltd has informed that the Company has successfully launched its fourth Research Product, a Fixed Dose Combination of Cephalosporin with aminoglycoside under the Brand name "TOBRACEF" in Domestic Market for the first time globally. 2009 -Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa. -Venus Bags Another Product Patent from South Africa for POTENTOX. --Registered Office of the Company has been shifted from SCO 39, Sector 26, Chandigarh. to SCO 857, C. No. 10, IInd Floor, NAC Manimajra, Chandigarh - 160 101. 2010 -Venus Remedies Ltd, a fast-growing pharmaceutical company in the country, has launched MEBATIC, a unique antibiotic combination in infusion form to cure severe gastro intestinal (GI) infections. -"Venus Remedies receives GMP Certification from Botswana". -Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits. -The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015. -Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent". 2011 -"Venus Remedies Anti-Cancer drug "GEMCITABINE" gets UK MHRA approval". -"Sulbactomax" patent from Mexico strengthens Venus Remedies' presence in Latin America". -"Venus Remedies successfully completes Phase I & II Clinical Trials of TUMATREK (VRP162O), cancer detection molecule". -Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011. -"Venus launches its patented research product ACHNIL" in India". -"Venus Remedies wins "India Manufacturing Excellence Award 2011". 2012 -VenusRemedis - Venus's ACHNIL, BioSpectrum Product of the Year 2012. -VenusRemedis - Innovative Solution for alleviating cancer. -"Venus Remedies introduces "Ready-to-Use" Single Vial Taxedol in India". -Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India -The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012". -"Venus wins Patent award in Silver Category". 2013 -"Venus Remedies launches Elores - CSE 1034, a US Patent projected product in India". -"Venus Remedies signs MoU for Elores with South African pharmaceutical firm". -"Venus Remedies takes its flagship product, Elores into Latin America". -"Venus launches its first OTC product Ezenus". -"Venus sign Exclusive Marketing Rights deal for its novel Antibiotic Ajuvant Entity to South Africas second largest Pharmaceutical Company - Adcock". -"Venus Remedies MEROPENEM receives market authorization in Mexico". -Venus Remedies Ltd has informed regarding "ELORES awarded Gold Medal for being the best Innovation of 2013" -"Venus wins Innovative 100 Award for ELORES". -"Venus bags UBM India Pharma Award for Elores". 2014 -"Venus ties up with Mylan for marketing meropenem in three European countries". - "VMRC Drug VRP008 to Fight "MULTI-DRUG Resistant Bacteria" Receives European Patent". -"Venus Receives Market Authorization for Meropenem from SWITZERLAND (SWISSMEDIC)". 2015 -"Venus announces issuance of Indian Patent for Vancoplus". -Venus Remedies holds blood, organ donation camps on its Panchkula premises. 2016 -"Venus launches its second OTC product "SWATCH GAURD" a herbal Hand Sanitizer". 2019 -"Venus announces deal with Cipla for its patented product Elores for Indian Territory". 2021 -Venus Remedies launched its full-fledged Consumer Healthcare Division. -Venus Remedies Limited has been selected for Production Linked Incentive Scheme (PLI) of the Government of India. 2022 -Venus Remedies won WHO Good Distribution Practices (GDP) certification for quality services across entire supply chain. -Venus remedies wins ambitionbox best places to work award. -Venus Remedies Limited has been Great Place to Work Certified.

2023
-"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model".
-"Venus Remedies Limited Honored with Best Working Conditions Award 2022".
-Venus Remedies launched flagship R&D drug Elores in Oman.
-Venus Remedies  oncology wing product registrations go up to 506 with marketing approvals from four more countries.
-"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities".
-'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'.

2023 -"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model". -"Venus Remedies Limited Honored with Best Working Conditions Award 2022". -Venus Remedies has launched its flagship R&D drug, Elores, in the USD 1.4-billion pharmaceutical market in Oman. -"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities.". -'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'.

2024 -Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product. -Venus Remedies awarded with Rs.2.50cr as the remaining part of its first incentive under PLi scheme. -Venus Remedies awarded its first incentive of Rs.7.50 crores under PLI scheme.